Home > Research > Scientific Programmes: Clinical Research Programme > Prostate Cancer Clinical Research Unit

Clinical Research Programme

Prostate Cancer Clinical Research Unit

Head of Unit:  David Olmos

Prostate cancer (PrCa) is the most common cancer and the 2 leading cause of cancer mortality among men in Western countries. Despite advances in diagnosis and early-disease treatment, up to 30% of PrCa patients will develop metastasis at some point and succumb after the acquisition of a castration-resistant status (mCRPrCa). The early identification of PrCa patients with greater predisposition to develop aggressive mCRPC could lead to the development of novel treatment strategies and improved outcomes. In addition to AR aberrations following androgen-deprivation therapy leading to resistance to current treatment options, DNA repair defects have been identified in about 5% and 25% of early PrCa and mCRPC, respectively. Seminal work from our Group, and others, has established that some alterations, e.g. germline BRCA1/BRCA2 deleterious mutations, are linked to poor outcomes. Currently, we lack the adequate biological knowledge and reliable biomarkers to select the right treatment for the right patient at the right time.